基于组织的生物标志物指导尿路上皮癌患者的临床决策

Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.

作者信息

Afferi Luca, Cimadamore Alessia, Gallioli Andrea, Pradere Benjamin, Mertens Laura S, Marcq Gautier, Anguera Georgia, Necchi Andrea, Briganti Alberto, Montorsi Francesco, Rouprêt Morgan, Gontero Paolo, Breda Alberto, Moschini Marco

机构信息

Department of Urology, Fundació Puigvert, Barcelona, Spain; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Institute of Pathological Anatomy, Department of Medicine, University of Udine, Udine, Italy.

出版信息

Eur Urol. 2025 Jan;87(1):1-4. doi: 10.1016/j.eururo.2024.08.033. Epub 2024 Sep 11.

DOI:10.1016/j.eururo.2024.08.033

PMID:39266382

Abstract

The European Association of Urology (EAU), National Comprehensive Cancer Network, and European Society for Medical Oncology guidelines recommend PD-L1 and FGFR testing for patients with locally advanced bladder cancer or upper tract urothelial cancer (UTUC) according to specific eligibility criteria; positive results indicate therapy with immune checkpoint inhibitors or erdafitinib, respectively. The EAU guidelines recommend PD-L1 testing for subsequent adjuvant therapy in high-risk UC, and germline DNA sequencing in patients with UTUC positive for DNA mismatch repair alterations.

摘要

欧洲泌尿外科学会（EAU）、美国国立综合癌症网络和欧洲医学肿瘤学会的指南建议，根据特定的入选标准，对局部晚期膀胱癌或上尿路尿路上皮癌（UTUC）患者进行程序性死亡受体1配体（PD-L1）和纤维原细胞生长因子受体（FGFR）检测；检测结果呈阳性分别表明可使用免疫检查点抑制剂或厄达替尼进行治疗。EAU指南建议对高危尿路上皮癌患者进行PD-L1检测以用于后续辅助治疗，对DNA错配修复改变呈阳性的UTUC患者进行种系DNA测序。